Table 3

Baseline characteristics of the patients
Characteristics Full analysis set Per-protocol analysis set
Trial n=175 Control n=175 t/χ2/Z P Trial n=155 Control n=151 t/χ2/Z P
Age (years) 66.33 ± 9.63 64.28 ± 9.42 −0.935 0.351 62.74 ± 9.87 64.66 ± 8.92 −1.778 0.076
Course of disease 169.56 ± 290.63 161.07 ± 128.45 0.353 0.725 166.86 ± 305.92 163.18 ± 131.84 0.136 0.892
BMI 24.26 ± 11.79 23.75 ± 3.10 0.543 0.587 24.41 ± 12.54 23.74 ± 3.09 0.643 0.521
Exacerbation
Frequency (times) 3.26 ± 2.27 2.94 ± 2.05 1.378 0.169 3.32 ± 2.31 2.95 ± 1.91 1.523 0.129
Duration (days) 2.78 ± 2.00 2.73 ± 1.97 0.228 0.820 2.82 ± 2.08 2.75 ± 1.81 0.319 0.750
Lung function
FVC (liters) 2.91 ± 0.95 2.81 ± 0.89 0.953 0.341 2.95 ± 0.97 2.81 ± 0.92 1.239 0.216
FEV1(liters) 1.46 ± 0.57 1.35 ± 0.46 1.465 0.144 1.46 ± 0.57 1.35 ± 0.46 1.747 0.082
FEV1% 49.89 ± 10.84 49.58 ± 12.07 0.244 0.807 49.94 ± 10.95 49.58 ± 12.36 0.266 0.790
Gender
Male 122 131 1.556 0.212 106 116 2.732 0.098
Female 54 43 49 35
Smoking status
Currently smoking 103 114 1.817 0.178 89 102 3.346 0.067
None-smoking 73 60 66 49
Smoking pack-years 380.91 ± 158.26 366.47 ± 150.32 0.686 0.493 377.08 ± 164.08 372.47 ± 154.47 0.199 0.843
GOLD classification
GOLD 1 14 6 −0.093 0.926 13 6 −0.369 0.712
GOLD 2 68 80 61 66
GOLD 3 94 88 81 79

The course of disease was calculated in months.

The body-mass index (BMI)is the weight in kilograms divided by the square of the height in meters.

Exacerbations during the 12 months before screening were self-reported.

Clinical data are from visit 1 (the screening visit). FEV1 denotes forced expiratory volume in 1 second, and FVC is forced vital capacity.

Li et al.

Li et al. BMC Complementary and Alternative Medicine 2012 12:197   doi:10.1186/1472-6882-12-197

Open Data